-
Monoclonal Antibody Bentracimab Shown to Reverse Antiplatelet Effect of Brilinta | ACC 2025
01 Apr 2025 22:04 GMT
… New England Journal of Medicine Evidence.
Brilinta, developed by AstraZeneca, … year granted it orphan drug designation. If approved, … by SERB Pharmaceuticals.
The REVERSE-IT trial was funded … minutes after starting bentracimab treatment.
Dr. Bhatt noted …
-
SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding
29 Mar 2025 16:32 GMT
… have been stented for treatment of ACS; 2 … most promising drug development programs of pharmaceutical and biotechnology companies. … consistently provided emergency medicines, medical countermeasures, and the … REVERSE-IT Trial. Late-Breaking Clinical Trials II [ …
-
ACC 2025: 7 Trials to Watch
28 Mar 2025 11:53 GMT
… for ticagrelor (Brilinta). Developed by SFJ Pharmaceuticals and set for … participants who take a statin and still have high … effects for months post-treatment.
The trial will be presented … of Medicine.
References:
Campbell P. ACC.24 Clinical Trials Recap, …
-
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
06 Feb 2025 14:13 GMT
… Global Medical Affairs, and US Development brand leader for BRILINTA.
… tecarfarin. Tecarfarin received Orphan Drug designation (ODD) for advanced … a pivotal Phase 3 trial evaluating tecarfarin versus … a pivotal Phase 3 trial evaluating tecarfarin versus …
-
Scientists Uncover Shocking Flaws: Investigation Questions Effectiveness of Popular Anti-Platelet Drug
01 Jan 2025 23:51 GMT
… ticagrelor, a drug approved by the FDA despite concerns about trial reliability and … of the anti-platelet drug ticagrelor (marketed as Brilinta in the US … ’s first application for FDA approval failed.
FDA medical officer Thomas Marciniak reviewed …
-
Malpractice Killed Mom; Opioid Giant Avoided Payout; Landmark Trial Questioned
01 Jan 2025 20:05 GMT
… where Ray sought treatment, and the medical staff associated with … wasn't a doctor. A medical expert reviewed Ray… a landmark trial for the antiplatelet drug ticagrelor (Brilinta), questions of … data integrity and other trials failed to replicate the …
-
Blood clot drug taken by millions of Americans may cause deaths from strokes, heart attack
13 Dec 2024 13:20 GMT
… of AstraZeneca's Brilinta, which is given to … vessel condition, the doctor might prescribe them a drug like ticagrelor.
… results from the American trials had to do with … dosing.
Thomas Marciniak, an FDA medical officer who reviewed this second …
-
Investigation raises new concerns over landmark trial for top selling anti-platelet drug
12 Dec 2024 02:04 GMT
… approval for the anti-platelet drug ticagrelor (Brilinta in the US and … ’s first application for FDA approval failed.
FDA medical officer Thomas Marciniak reviewed … Title
Doubts over landmark heart drug trial: ticagrelor PLATO study
Article Publication …
-
Doubts over landmark heart drug trial: ticagrelor PLATO study
12 Dec 2024 01:27 GMT
… decade the antiplatelet drug ticagrelor (Brilinta in the … established in the treatment of acute coronary … FDA medical officer with an atypical reputation for thorough reviews of drug … trial “has no reason to be challenged,” but argues that subsequent trials …
-
New Investigation Casts Doubt on Landmark Ticagrelor Trial
13 Dec 2024 10:04 GMT
… the landmark trial that launched the antiplatelet drug ticagrelor worldwide … generic versions of ticagrelor (Brilinta) are expected to … by some FDA staff members, including medical officer Thomas … readjudicating in the current treatment era."
Other calls …